Safa Can Efil

8PUBLICATIONS
44CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|Jan 10, 2026
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study.

Safa Can Efil, Fatih Kus, Bahadir Koylu

|Oct 24, 2025
Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma.

Doğan Bayram, Safa Can Efil, Serap Türk

|Oct 04, 2025
Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study.

Safa Can Efil, Sema Nur Ozsan Celebi, Beste Ozturk

|Jul 21, 2025
Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer.

Furkan Ceylan, Didem Şener Dede, Safa Can Efil

|Feb 25, 2025
Correlation of PD-L1 and HIF-1 Alpha Expression with KRAS Mutation and Clinicopathological Parameters in Non-Small Cell Lung Cancer.

Seda Er Özilhan, Safa Can Efil, Doğukan Çanakçı

Pageof 2

Frequent Collaborators

4 joint publications

Mehmet Ali Nahit Şendur

3 joint publications

Burak Bilgin

3 joint publications

Serhat Sekmek

2 joint publications

Furkan Ceylan